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Abstract
Tirandamycin is a small molecule natural product that has been isolated from various species
of marine and terrestrial Streptomyces. The natural product has shown antibacterial activity
against an array of Gram-positive and Gram-negative bacteria, showing promise as a
pharmaceutical drug. Tirandamycin has 14 known derivatives, many of which have been
created synthetically. Some of its derivatives are particularly potent against the high-risk
bacteria vancomycin-resistant Enterococcus faecium, Staphylococcus aureus, Streptococcus
agalactiae, Streptococcus pneumoniae and Escherichia coli. However, the antibacterial
potency of these derivatives has not been tested systematically leading to the possibility of
discovering more potent derivatives of the drug which could combat the rise of multi-drug
resistant forms of these bacteria. Additionally, understanding tirandamycin’s structural basis
of inhibition would allow for future manipulation of tirandamycin’s base structure to maximize
antibacterial potency. While it is known that tirandamycin targets bacterial RNAp, there is still
a need to determine where tirandamycin specifically binds to the enzyme, including the
interactions between its amino acid residues and tirandamycin. A screening of the derivatives
of tirandamycin against these high-risk bacteria is proposed to discover possibly potent but
currently untested derivatives of tirandamycin. Additionally, x-ray crystallography of the
tirandamycin-RNAp complex and site-directed mutagenesis of E. coli RNAp is proposed to
determine the structural basis of inhibition by tirandamycin.
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I. Introduction
a. Overview of natural products
The use of natural products produced by plants, animals, and microorganisms has been
common throughout history, with some of the earliest known uses dating back to 1500 BCE
Egypt.1 In the past hundred years, the science behind these natural products has developed, and
they can now be understood in a biological and chemical context. This allows for their
antibacterial or antifungal potency to be dramatically increased as well as their structural basis
of inhibition to be uncovered. This information can be used to chemically manipulate their
structure to better bind and inhibit a target resulting in more effective and less toxic medicines.
Due to the wide range of organisms that produce these natural products, thousands have
been categorized to date, all with unique structures that target different bacteria and fungi, and
some even emerging as chemotherapeutic agents.2 The 3-acyltetramic acid family of natural
products contain important microbial derived antibiotics, including tirandamycin A and B,
tirandalydigin, streptolydigin, nocamycin, and Bu-2313 A (Figure 1).3
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Figure 1. Structures of natural products in the tetramic acid family. The common structural
features including the epoxide (pink), C-18 methyl (orange), ketone (blue), and pyrrolidine2,4-dione (green) groups are highlighted.

The tetramic acid family of natural products are usually isolated from terrestrial and marine
organisms, including bacteria, fungi, and sponges, and they exhibit antitumor, antibacterial,
and antiviral activities.4 Each differs in the degree of oxidation of their bicyclic ketal ring
system as well as the pyrrolidine-2,4-dione substituents (Figure 2). By comparing their
structures and biological activities, a description of how these chemicals work from a
microbiological stance is beginning to emerge. Possible routes for chemical modifications of
5

these products that can lead to novel, more potent, antibacterial and chemotherapeutic drugs
with lower levels of cell toxicity are also being developed.5–8

Figure 2. Pyrrolidine-2,4-dione and bicyclic ketal ring system structures of the tetramic
acid family of natural products as seen on tirandamycin A.

b. Tirandamycin as a target for pharmaceutical research
Tirandamycin has been shown to be an antibacterial agent effective against an array of
Gram-positive bacteria, including vancomycin-resistant enterococcus (VRE), and the Gramnegative Escherichia coli (Table 1).9,10 Additionally, tirandamycin has been shown to have
little to no cytotoxic activity in human cells.5,11 It is important to recognize that tirandamycin
is not the most potent antibacterial in the tetramic acid family of natural products as
streptolydigin is a better antibacterial agent against E. coli.10 However it offers promise for the
6

development of new medicines because the chemical synthesis of multiple derivatives of this
compound has already been achieved.12–14 Therefore, to develop tirandamycin into a useful
pharmaceutical drug, its potency must first be optimized. This can be done by uncovering the
mechanism behind tirandamycins function as a generic anti-bacterial.

Minimum Inhibitory Concentration (μg/ml)
GramStain

(-)
(+)
(+)
(+)
(+)

Bacteria

A

Escherichia coli

10019

(+)
(+)
(+)
(+)
(+)
(+)

Streptococcus faecalis
Streptococcus hemolyticus
Streptococcus pneumoniae
Streptococcus pyogenes

(+)
(+)

8
0.949
25018

>12816

2.55
5019

2.55

18

C

D

0.30215
117
3216
10017
43.359

Bacillus halodurans
Bacillus thuringiensis
Bacillus subtilis
Vancomycin-resistant
Enterococcus faecium
Staphylococcus areus
Multi-drug-resistant
Staphylococcus aureus
Streptococcus agalactiae
Streptococcus bovis

B

4.849
4.8415
9.6915

K

L

Iso-B

39.5315

>3.619

79.0615
>158.1115
>158.1115

12816
>12816
>12816
5.05

<0.518
<0.518
<0.518
12.519

Table 1. Minimum inhibitory concentration of tirandamycin derivatives against Bacillus,
Escherichia, Enterococcus, Staphylococcus, and Streptococcus genus bacteria. Each derivative
is represented by its letter, where Iso-B stands for isotirandamycin B.5,9,15–19

Tirandamycin is a secondary metabolite that has been isolated from several species of
marine and terrestrial Streptomyces and their mutant strains.20 As most products in the tetramic
acid family, it features a bicyclic ketal moiety at the end of a conjugated 5 carbon chain.21
There are currently 14 known tirandamycin derivatives existing both naturally and as
genetically engineered intermediates (Figure 3).5,9,11,15,16,22 These derivatives all vary in their
bicyclic ketone degree of oxidation, stereochemistry, and connectivity. Common structural
7

features include the tetramic acid, epoxide, ketone, and methyl groups, as well as a C-4 C-5
trans conformation.
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Figure 3. Structures of the 14 derivatives of tirandamycin with common structural features
highlighted. The epoxide (pink), methyl (orange), ketone (blue), and pyrrolidine-2,4-dione
(green) groups are highlighted. Additionally, the C-4 C-5 trans isomers are shown in red. The
carbon numbering of tirandamycin is shown on structure A.

Structure-activity relationships (SARs) are a key aspect of optimizing drug potency and
represent the relationship between a compounds structure and its biological activity.23 SARs
are particularly important to examine when comparing the potency of tirandamycin’s
derivatives, as the different substituents on the bicyclic ketal ring of each derivative will likely
have an effect on how potent they are. According to SARs, the most potent structures should
have substituents or functional groups that are interacting with the target enzyme and are
important for tirandamycins biological activity. Alternatively, some derivatives may have
unnecessary substituents or functional groups that would have no effect on the biological
activity of tirandamycin. This would be represented as two derivatives with equal potency
towards a specific bacterium with only one having an extra substituent or functional group
attached. By measuring the antibacterial potency of tirandamycin's derivatives, scientists have
been able to uncover the importance of structure-activity relationships and come closer to
finding the mechanism behind some of tirandamycin’s antibacterial properties.

c. The antibacterial activity of tirandamycin
Shortly after its discovery in 1971, tirandamycin A was tested for antibacterial activity
against an array of Gram-positive bacteria of the Bacillus, Staphylococcus and Streptococcus
genus.18 The natural product showed potent antibacterial activity towards B. subtilis, S.
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faecalis, S. hemolyticus, and S. pneumoniae with minimum inhibitory concentrations (MICs)
of 8 μg/ml, < 0.5 μg/ml, < 0.5 μg/ml, and < 0.5 μg/ml, respectively. Tirandamycin A and its
many derivatives have since been tested for antibacterial activity against a wider range of
Bacillus, Streptococcus, Staphylococcus, Enterococcus, and Escherichia bacteria.
Tirandamycin is a known inhibitor of bacterial ribonucleic acid polymerase (RNAp), as
shown in a study that tested tirandamycin A for inhibition of the RNAp of E. coli and the
RNAp from rat liver nuclei.10 Bacterial RNAp is an enzyme responsible for RNA initiation,
elongation and termination.24,25 The α, β, β’, and ω subunits make up the core enzyme. The σ
factor is a separate protein that binds to the core RNAp to form the holo-enzyme and allows it
to locate specific DNA promoter sequences within the double-stranded DNA (Figure 4). After
RNAp binds to DNA, the DNA template must move through the enzyme for RNA
transcriptions, a process referred to as translocation.26 During this process, the “F bridge helix”
in the β’ subunit alternates between a straight and bent structure, causing a conformational
change in the enzyme that lets each amino acid of the DNA template into the active center to
be transcribed into the corresponding RNA amino acid.27 This process is vital for RNAp
function. Whereas tirandamycin was able to effectively inhibit the chain initiation and
elongation of bacterial RNAp, it had no effect on the function of animal polymerase. This
provides evidence that tirandamycin could be safe for use on humans. Additionally, it shows
tirandamycins likely bacterial target, and suggests that tirandamycins potency might vary for
each species of bacteria due to differences in their RNAp amino acid sequence.
Although the specific molecular interactions between bacterial RNAp and tirandamycin
are still unknown, the suggested binding interactions of RNAp and the natural product
streptolydigin have been studied. Both tirandamycin and streptolydigin have a bicyclic ketal
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group at the end of an unsaturated 6 carbon chain and have been compared as structurally
analogous to each other, making data collected from one natural product presumed to be
applicable to the other.9
The x-ray crystal structure of the streptolydigin-RNAp complex provides a picture of its
general binding site on the enzyme. This technique was used to uncover streptolydigin as an
allosteric inhibitor of Thermus thermophilus RNA polymerase, stabilizing the straight-bridge
helix conformation and preventing the cycling into a bent-bridge helix conformation.4 The xray crystal structure showed the natural product binding to an area on the β and β′ subunits of
bacterial RNAp, interacting with the trigger loop region and bridge helix of the enzyme (Figure
4).

Figure 4. Structure of E. coli RNAp with five subunits (left) and potential tirandamycin
binding site (right) pictured. The α subunit is shown in red, β subunit in pink, β' subunit in
yellow, ω subunit in salmon, and the attached σ70 factor is shown in white. The proposed
binding site of tirandamycin is shown in green with the amino acids that are presumed critical
for streptolydigin binding labeled.
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In addition to this, the study did saturation mutagenesis and analysis of T. thermophilus to
find amino acid substitutions that lead to streptolydigin-resistant RNAp. Substitution of small,
hydrophobic amino acid residues 543 Ala and 544 Gly in the β subunit to larger, more
hydrophilic residues Val and Arg caused RNAp streptolydigin resistance. This suggests that
there are favorable hydrophobic interactions at C-4, C-5, C-15, and C-16. Additionally, the
authors suggest that the amino acid substitution of residue 788 Leu to Val introduces a
branched side chain that likely results in steric hinderance at C-18, C-10 and C-11 for
streptolydigin binding. These interactions are likely to contribute to tirandamycins biological
activity, as both compounds are structurally similar in these specific areas having methyl
groups at C-4 and C-6 on their linear six carbon chain and an epoxide group at C-12 on their
bicyclic ketal moiety. Because of the high degree of RNAp sequence conservation between
bacteria, the T. thermophilus RNAp structure is considered an accurate model representative
of the transcription apparatus in all bacteria.29 This allows the data collected with streptolydigin
and T. thermophilus to be applicable to many different species of bacteria. The close
relationship between the natural products streptolydigin and tirandamycin also suggests it is
likely that tirandamycin binds to the same location on bacterial RNAp and uses the same
structural basis of inhibition as streptolydigin. The results of other studies which have
compared the antibacterial potency of different tirandamycin derivatives against other bacteria
give further information about the structure-activity relationship presumably between
tirandamycin and bacterial RNAp (Figure 5).
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Figure 5. Annotated structure of tirandamycin with predicted structure-activity
relationships shown.

There are some discrepancies in the data collected on the potency of tirandamycins
derivatives, likely due to the fact that they have been evaluated in many different experiments
but never all together. This can provide mixed reviews on whether certain functional groups
are important for tirandamycins biological function. It is important, however, to take all the
data into account to understand all the current theories about the SARs of tirandamycin.
Tirandamycins A and B were isolated and characterized from a marine-derived
Streptomyces sp. along with intermediates C and D.9 Analysis of these metabolites occurrence
in the biosynthetic pathway showed that tirandamycin C was the earliest intermediate, followed
by tirandamycin D, A, and B. Due to the increasing level of oxidation on the bicyclic ketal
rings with each succeeding derivative, the authors came to two conclusions. First, it is likely
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that the epoxide group on carbon-11 and carbon-12 of tirandamycins bicyclic ketal rings is
necessary for tirandamycin’s function. Second, both tirandamycin A and B are present as final
products in which the only difference is the addition of a hydroxyl group on the carbon-18
methyl. The authors suggest that this step may not be necessary for tirandamycin’s function,
and therefore both derivatives are abundantly produced final products. This would suggest that
it is the step of adding the epoxide group which is introduced after tirandamycin C in the
biosynthetic pathway that gives these products their antibacterial properties.
In addition, the paper looked at the activity of tirandamycin A through D against VRE, and
the results agreed with the importance placed on the C-11 C-12 epoxide group. Tirandamycin
A (MIC = 2.25 μM) was drastically more potent than tirandamycin B (MIC = 100 μM), C
(MIC = 110 μM), and D (MIC > 9 μM). From the data it was inferred that the increased potency
of tirandamycin A could be attributed to the C-10 ketone and C-11 C-12 epoxide. The hydroxy
group at C-18 on tirandamycin B was proposed to have an adverse effect on tirandamycin’s
antibacterial activity, as its potency was similar to that of tirandamycin C.17 It can be
extrapolated from this data that oxidation of carbons inside the bicyclic ketal ring system may
help tirandamycin better inhibit VRE, while building oxygen containing substituents onto C18 could cause steric hindrance between tirandamycin and its binding site.
In contrast to its poor anti-VRE activity, tirandamycin B was found to be about equally
effective against Streptococcus agalactiae (MIC = 5.7 μg/mL) as tirandamycin A (MIC = 5.9
μg/mL). In addition to these derivatives, a new tirandamycin analogue, isotirandamycin B, was
tested against S. agalactiae and had a significantly weaker effect on the bacteria, with an MIC
of 11.5 μg/mL. These results suggest that the presence of a hydroxy group at carbon-18
increases rather than inhibits tirandamycins antibacterial potency against S. agalactiae. The
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additional testing of isotirandamycin B suggests another interesting component of
tirandamycins structure. Isotirandamycin B has a completely identical structure to
tirandamycin B but has undergone E to Z isomerization of the carbon-4 carbon-5 double bond.
This shows the trans conformation of tirandamycins carbon chain is likely necessary for
tirandamycin’s function.5
When tested against Bacillus thuringiensis, tirandamycin B has significantly more potent
antibacterial activity compared to tirandamycin L, with MICs 32 μg/mL and 128 μg/mL,
resepectively.16 Derivative B and L are structurally identical compounds with two exceptions,
tirandamycin L does not have the epoxide group connecting C-11 and C-12 or the hydroxyl
group on C-18 that B has. This suggests that, similarly to S. agalactiae, the oxidative
modification of the bicyclic ketone group on tirandamycin is important for its antibacterial
activity against B. thuringiensis.
Tirandamycin K, the first linear tirandamycin derivative, was isolated along with
tirandamycin C. Both derivatives were tested for antibacterial activity against Escherichia coli,
VRE, Staphyloccus aureus, and multidrug resistant S. aureus. In all cases, tirandamycin C
showed significantly more potent antibacterial activity than tirandamycin K, which had no
effect on S. aureus at up to 400 μM. Therefore, this study concluded that the bicyclic ketal
rings are likely necessary for antibacterial function.15
As bacteria continue to evolve and mutate, the need for new antibacterial drugs with
different modes of action is of constant importance. The emergence of multi-drug resistant
bacteria including VRE, S. agalactiae, group A and B Streptococcus, S. aureus, and E. coli
have global health implications and these issues must be addressed by constantly searching for
novel antibacterial chemicals that can combat this phenomenon.30–33 In addition to this,
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penicillin-resistant and multi-drug resistant S. pneumoniae has become a growing issue as one
of the leading causes of pneumonia and meningitis.34,35 It is important to capitalize on the
discovery of tirandamycin, whose many derivatives offer another way to combat these bacteria
while they are evolving to be immune to current medicines, which are slowly becoming less
and less potent.36 Aim 1 will address this need by conducting a larger screening of the current
known tirandamycin derivatives A-L against the listed bacteria.
Additionally, the bacteria Escherichia coli seems to be a particularly good target for further
research regarding the possible pharmaceutical implications of tirandamycin. E. coli is
responsible for a wide range of infections including urinary tract infections and pneumonia.37,38
In intensive care units, ventilator-associated pneumonia has a mortality rate of around 13%
with higher rates for surgical patients.39 Escherichia coli has been shown to be one of the most
common causes of ventilator-assisted pneumonia, second only to Pseudomonas aeruginosa.40
With the emergence of ampicillin, cefotaxime, and multi-drug resistant strains of E. coli, the
World Health Organization named Enterobacteriaceae, including E. coli, critical priority
pathogens.41–43 While many of the compounds in the tetramic acid family of natural products
have antibacterial properties against E. coli, only the mechanism of streptolydigin has been
studied.10,19,28 Due to the structural similarities between streptolydigin and tirandamycin, it is
likely that these two natural products use the same mechanism of action.9 However, further
data are needed to confirm this relationship. Discovery of tirandamycin’s interaction with E.
coli RNAp would create a further understanding of how these natural products inhibit bacterial
RNAp and provide the information needed for the rational design of more potent antibiotics
based on tirandamycin’s structure. Aim 2 will further the understanding of this interaction by
using x-ray crystallography of E. coli RNAp interacting with tirandamycin to create an image
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of where tirandamycin interacts with E. coli on bacterial RNAp and showing what amino acids
may be present at that binding site.
Aim 3 proposes making single amino acid substitutions at the binding site of tirandamycin
determined in aim 2 using site-directed mutagenesis on E. coli RNAp to determine the specific
amino acid interactions that contribute to tirandamycins SARs. Amino acid substitutions that
cause E. coli RNAp resistance to tirandamycin would suggest there are interactions happening
between tirandamycin and the amino acid that are crucial for tirandamycins biological activity.
By finding these critical amino acid residues, the structure of tirandamycin could be
manipulated to form more favorable interactions between bacterial RNAp and the natural
product, allowing for the creation of more potent forms of tirandamycin.
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II. Research Proposal
a. Aim 1: Screening of tirandamycins A-L against VRE, group A and B S. agalactiae, S.
aureus, S. pneumoniae and E. coli.
Tirandamycins A, B, C, and K have been the main focus of research regarding the bacteria
E. coli, VRE, S. agalactiae, and S. aureus; however, these derivatives have mainly been tested
individually and not in comparison to one another. In addition, tirandamycins E through L have
rarely been tested for any kind of antibacterial activity at all. To move forward in the
development of novel chemicals to combat the drug resistant bacteria VRE, group A and B S.
agalactiae, S. aureus, S. pneumoniae and E. coli, all tirandamycin derivatives should be
compared on the basis of their antibacterial activity against these pathogens and their structure
to accurately deduce how to optimize their potency. These specific bacteria have been chosen
because tirandamycin has already been shown to be a potent antibacterial of Streptococcus,
Staphylococcus, Enterococcus, and Enterobacteriaceae. Additionally, vancomycin-resistant
Enterococcus faecium, Staphylococcus aureus, Streptococcus pneumoniae, and Escherichia
coli have been labeled as "global priority pathogens" by the World Health Organization, and
Group A and B S. agalactiae have been listed as a "concerning threat" by the CDC due to their
growing resistance to erythromycin and clindamycin.43–46
Aim 1 will determine the most potent structure of existing tirandamycin derivatives using
drug screening of tirandamycins A through L against VRE, group A and B S. agalactiae, S.
aureus, S. pneumoniae, and E. coli. Vancomycin-resistant enterococcus would be spread on
m-Enterococcus Agar in 96-well plates and spotted with 100 μl serial dilutions of the
derivatives of tirandamycin listed above, including isotirandamycin B in dimethyl sulfoxide
(DMSO). Dilutions will start at 200 μg/ml, going down by a concentration of 10 μg/ml until
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the minimum inhibitory concentration (MIC) of each derivative is reached (Figure 6).42–45
MICs would be calculated by finding the smallest concentration of tirandamycin that still has
a clear zone of inhibition. This process would be repeated for S. agalactiae, S. pneumoniae,
and S. aureus on Blood Agar, and E. coli on Nutrient Agar.9 All bacteria would be incubated
for 24 hours at 35 °C to facilitate bacteria growth.49,51–54

Figure 6. Serial dilutions shown in μg/ml of tirandamycin to 20% DMSO solution.

DMSO would be an optimal solvent to use, as it has been successfully used as a solvent in
studies with Streptococcus pneumoniae and Staphylococcus aureus previously and has been
tested against Escherichia coli, showing no inhibition of the bacteria when using up to 20%
DMSO by volume to solid medium agar.55–57 Additionally DMSO is known to be a strong
organic solvent which can dissolve both hydrophobic and hydrophilic compounds making it
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ideal for the derivatives of tirandamycin, a compound with hydrophilic bicyclic moiety and
tetramic acid structure and a hydrophobic carbon chain.58 While DMSO has been used as a
solvent for the Gram-negative E. coli and three of the five selected Gram-positive bacteria, the
toxicity effects of various organic solvents has been shown to vary across Gram-positive
bacteria based on their specific species making the effect of DMSO on group A and B S.
agalactia, and VRE unknown.59 Due to this variation, DMSO could have an inhibitory effect
on these Gram-positive bacteria. Therefore, the agar plates would also be spotted with 100 μl
of 20% DMSO as a negative control to ensure the solvent is not contributing to inhibition of
growth. If DMSO at 20% concentration by volume is shown to inhibit growth of the bacteria,
the serial dilutions should be repeated using an alternative solvent such as methanol which has
also been shown to have low levels of toxicity against various Gram-positive bacteria and can
dissolve organic materials.56 The concentration of DMSO and methanol to water can also be
increased in the case of low tirandamycin solubility or decreased due to bacterial inhibition.
The previously studied tetramic acid streptolydigin would also be spotted on agar plates of
S. aureus and E. coli using the same serial dilutions and solvent concentrations, as a positive
control. This would allow the effect of experimental conditions such as the chosen solvent or
solvent concentration on the antibacterial potency of streptolydigin and therefore tirandamycin
to be evaluated. Streptolydigin would be a good positive control as it has been previously tested
for antibacterial activity against S. aureus and E. coli.19 Tirandalydigin, another tetramic acid
analogue, would be used as a positive control for VRE because it's MIC for vancomycinresistant Enterococcus faecalis is also known.19 Besides tirandamycin, there are no products
in the tetramic acid family that have been tested against S. pneumoniae and S. agalactiae.
Therefore ceftriaxone, a known antibacterial agent for both, would be used as a positive control
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for these bacteria.60,61 The solvent type and concentration would be the same as used for the
tirandamycin derivatives across all positive controls.
The inhibitory effects of tirandamycin would be measured using the MICs of each
derivative for the 7 bacteria tested, providing a total of 91 MIC values. Due to potential
differences in the RNAp amino acid sequences of each individual bacteria, it is likely that the
most potent tirandamycin derivative will not be the same for all 7 bacteria. Organizing the
derivatives of tirandamycin in order of potency for each individual bacterium would make it
possible to analyze the affect certain functional groups and substituents have on tirandamycin
potency. Because each derivative would be tested using the same experimental conditions, this
data would provide a far clearer and more accurate picture of the structure-activity
relationships of tirandamycin than the fragmented data currently available. Specifically, a
comparison of tirandamycins A and H with the tirandamycin derivatives D and L could provide
information as to whether the C-11 C-12 epoxide group is necessary for tirandamycins
biological activity. A comparison of tirandamycin A and isotirandamycin B would also show
how a trans to cis conformation change on the C-4 C-5 double bond affects tirandamycin
potency. As previously mentioned, the hydroxyl group on C-18 of tirandamycin B has been
predicted to have an adverse effect on tirandamycins antibacterial activity against vancomycinresistant Enterococcus due to steric hindrance. This proposal could be tested by comparing the
minimum inhibitory concentrations of tirandamycin A, B, and J. If added functional groups at
C-18 cause steric hindrance between tirandamycin and bacterial RNAp, then derivatives A, B,
and J should exhibit decreasing potency with functional groups of increasing size.
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b. Aim 2: X-ray crystallography of tirandamycin in complex with E. coli RNA polymerase
Knowing the location of tirandamycin's binding site on bacterial RNAp is necessary to
increase tirandamycin’s potency, as it can identify key interactions between the functional
groups of the antibiotic and the amino acid residues of the enzyme. Structural studies be done
using x-ray crystallography of a E. coli RNAp in complex with tirandamycin. In order to
determine where the most favorable interactions take place between tirandamycin and RNAp,
the tirandamycin derivative that had the lowest MIC for E. coli RNAp in aim 1 should be used.
X-ray crystallography would be ideal for E. coli RNAp because crystallization of the enzyme
has been successfully achieved using the E. coli σ70 holoenzyme.62 This not only proves that
the crystallization of E. coli RNAp is possible but removes the need for a "crystal screen" as
the most effective choice of precipitant, buffer, protein concentration, temperature, and
crystallization technique are all known.63–67
While the x-ray crystal structure of the E. coli RNAp-tirandamycin complex has not yet
been determined, an E. coli RNAp-benzoxazinorifamycin complex and T. thermophilus
RNAp-streptolydigin complex has been crystallized.28,68,69 From looking at the binding site of
streptolydigin on T. thermophilus it can be assumed that tirandamycin binds at the same
location between the β and β' subunits of E. coli RNAp.28 Both studies regarding
benzoxazinorifamycin and streptolydigin used the same technique to form the enzymecompound complex crystal structures however, it is possible that small differences between
the compounds or enzymes previously used could cause issues to arise when using the same
procedure for E. coli and tirandamycin. Specifically, benzoxazinorifamycin binds to a different
area on the β subunit of E. coli RNAp than where tirandamycin is presumed to bind.69 While
there is evidence that tirandamycin acts as an allosteric inhibitor of bacterial RNAp and forces
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a conformational change in the enzyme, benzoxazinorifamycin is not an allosteric inhibitor
and instead blocks the active site of RNAp.70 Additionally, T. thermophilus and E. coli share
many conserved residues; however, there are some differences between the two enzymes that
could affect the ability for the RNAp-tirandamycin complexes to form.28 To account for this,
suggested changes to the procedure for RNAp-tirandamycin complex crystallization are given.
Aim 2 will locate the tirandamycin binding site on E. coli RNAp using x-ray
crystallography of both the bacterial RNAp alone and tirandamycin interacting with bacterial
RNAp. As described in previous studies, E. coli RNAp core and σ70 holoenzyme would be
prepared and purified by creating a polycistronic plasmid, pGEMABC, for expressing the rpoB
and rpoC genes responsible for encoding the β and β′ subunits.64 The core RNAp subunits
would

be

transformed

with

pGEMABC

and

pACYCDuet-1_Ec_rpoZ.

Column

chromatography would be used for purification of E. coli RNAp after adding excess σ70 to core
RNAp. The RNAp crystals would be obtained using hanging drop vapor diffusion. A 50/50
mixture of protein solution and crystallization solution would be incubated at 22 °C over the
reservoir.69
For crystallization of E. coli RNAp in complex with tirandamycin, RNAp crystals would
be soaked in crystallization solution containing 20 mM MES, 13 mM magnesium formate, 2
mM spermine, 2 mM DTT, 5% PEG400, 10% MPD, and 0.1 mM of tirandamycin overnight
at 22 °C and flash frozen by liquid nitrogen. This procedure has been used previously for the
enzyme-crystal structures using rifamycin and streptolydigin. The two procedures used the
same concentration of drug (0.1 mM) but varied in the period of time which the crystals were
soaked. The T. thermophilus crystal was soaked in streptolydigin for only 15 minutes while
the E. coli crystal was soaked benzoxazinorifamycin overnight. Previous studies have shown
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that if the desired compound is not binding to the crystallized enzyme, increasing the period
of time which crystallized enzymes are soaked in the desired compound as well as increasing
the concentration of the compound in solution can help the complex crystals form.71 Therefore,
if the procedure mentioned above does not result in crystals with tirandamycin bound to E. coli
RNAp, E. coli RNAp holoenzyme should be soaked in tirandamycin using higher
concentrations of the compound for longer periods of time. As a negative control, E. coli RNAp
crystals should also be soaked in a crystallization solution without the added tirandamycin to
ensure the solution does not cause any conformational change of E. coli RNAp on its own.
The crystal structures of E. coli RNAp and the E. coli RNAp-tirandamycin complex will
be compared first to observe any conformational change induced by tirandamycin. A straightbridge helix conformation would be expected for the RNAp-tirandamycin complex, as was
seen in the T. thermophilus RNAp-streptolydigin complex. The crystal structure will also show
the location of tirandamycin’s binding site, allowing for the visualization of all amino acids in
contact with the structure of tirandamycin. Interacting hydrogen, oxygen, and nitrogen atoms
between tirandamycin and the amino acid residues of E. coli RNAp would be examined for
bond length, as an estimated 1.5-2.5 Å between a hydrogen atom and a nitrogen or oxygen
atom would indicate possible hydrogen bonding.72,73 Hydrophobic interactions and possible
sources of steric hindrance could also be studied using the crystal structure. This information
would provide a basis for the structure-activity relationships of tirandamycin.

c. Aim 3: Site-directed mutagenesis of E. coli RNAp
Site-directed mutagenesis is a valuable tool that can be used to determine structure-function
relationships between enzymes and inhibitors.74 This can be readily done to make mutants of
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E. coli RNAp because the primary DNA sequence encoding each individual subunit of the wild
type enzyme, which is required for site-directed mutagenesis, is already known.75 Once the
binding site for tirandamycin on E. coli RNAp is confirmed, site-directed mutagenesis can be
used to verify the amino acids that are crucial to tirandamycins binding affinity and its function
as an antibacterial. On the enzyme’s five subunits, it is likely tirandamycin would bind on the
β and β' subunits, interacting with the trigger-loop region and bridge helix.28 By comparing the
amino acids of T. thermophilus RNAp that streptolydigin binds to with the corresponding
amino acid residues in E. coli RNAp, it is possible to predict what type of interactions
tirandamycin has with E. coli RNAp (Figure 7). The effect each amino acid mutation has on
tirandamycins antibacterial activity will be evaluated by testing the MIC of tirandamycin for
each E. coli mutant RNAp, as described below.

Figure 7. Streptolydigin-thermophilus crystal structure, with critical amino acids around
streptolydigins bicyclic ketal ring and C-4 C-6 methyl groups labeled (green). Streptolydigin
is shown in pink, interacting with the β (blue) and β’ (orange) subunits of T. thermophilus.
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Based on the known crystallography data, it is likely that amino acid residues 543 Ala, 544
Gly, and 545 Phe on the β subunit of E. coli RNAp have hydrophobic interactions with the C4 through C-6 carbon chain and methyl groups on tirandamycin. To test this assumption, Asn
should be substituted for residue 545 Phe, introducing a relatively large polar amino acid in
the place of the wild type hydrophobic benzyl group at this position. Additionally, the much
smaller hydrophobic amino acid Ala should be substituted at this position. If this substitution
causes an increase in tirandamycin potency it could be possible that steric hindrance with the
C-4 and C-6 methyl groups interferes with tirandamycin’s ability to bind to bacterial RNAp,
and removing one or more of these groups would result in a more potent form of the drug. Two
mutations should also be made for both 543 Ala and 544 Gly to test for hydrophobic
interactions and steric hindrance at this position by substituting each with the larger amino acid
Leu and the polar amino acid Ser.
The conserved β' subunit residues 784 Asp, 787 Leu, and 788 Leu on T. thermophilus
RNAp were also shown to be important for streptolydigin’s binding affinity and should be
examined for possible interactions between E. coli RNAp and tirandamycin. Specifically,
substitution of Leu 788 to Val caused streptolydigin resistance in the bacterial RNAp, most
likely due to steric hindrance at the β carbon. It is important to note that this residue is near the
epoxide group on streptolydigin which is attached solely to C-12, while on tirandamycin this
epoxide group is attached to both C-11 and C-12. It is possible that this attachment to both
carbons changes the positioning of the epoxide resulting in decreased steric hindrance between
tirandamycin and amino acid residue Leu 788. This mutation should therefore be done when
testing E. coli to see if it leads to tirandamycin resistance. If hydrophobic interactions between
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the 788 Leu and C-12 and C-18 are important for tirandamycins binding affinity, substituting
Ala at this position should decrease tirandamycin potency.
The backbone of residues 784 and 787 are thought to interact with the C-12 epoxide group
as well as C-11 and C-10 on streptolydigins bicyclic ketal moiety. It is possible that hydrogen
bonding between the peptide backbone at this position and the oxygen groups on tirandamycin
may be a crucial part of tirandamycins structural basis for inhibition, as increased oxygenation
of this region of tirandamycin has previously shown to cause an increase in potency. Single
amino acid mutations of each of these residues to Pro would change the structure of this
backbone and could potentially remove the possibility of hydrogen bonding and lead to
tirandamycin resistance.
Using this information, new and improved tirandamycin analogues could be created by
examining which functional groups are interacting with these amino acids and how the
structure could be manipulated to create more favorable interactions between the wild type
enzyme and tirandamycin analog. The amino acid substitutions of tirandamycin resistant E.
coli RNAp mutants would correspond to specific residues that effect tirandamycins ability to
bind or inhibit the RNAp, further explaining tirandamycins structural basis for binding.
It is important to consider the effect which these single amino acid mutations would have
on the conformation and enzymatic activity of E. coli RNAp in the absence of tirandamycin
when evaluating the results of site-directed mutagenesis. It is possible that certain single amino
acid residue changes affect the conformation of E. coli RNAp enough to cause the enzyme to
lose its function in the absence of tirandamycin. In one study, a mutation which caused a single
amino acid substitution of the β subunit on E. coli RNAp blocked E. coli cell growth at 42 °C,
the temperature at which E. coli RNAp must be heated to for transformation to occur.76
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Because there is evidence that tirandamycin binds to the β subunit of E. coli RNAp, it is likely
that the β subunit would be targeted in site-directed mutagenesis. Therefore, a control
experiment to ensure enzymatic activity after each single amino acid substitution would be
needed. Additionally, a mutation in the enzyme could allosterically block the binding site of
tirandamycin.77 Crystallization and x-ray crystallography of each tirandamycin-resistant E.
coli RNAp enzyme should be evaluated for conformational changes that might block the
tirandamycin binding site. Additionally, it is possible that by artificially packing the enzyme
in a crystal structure, its natural conformation is altered. These control experiments are further
described in the procedure below.
Aim 3 would use site-directed mutagenesis to locate the amino acid residues that are crucial
for tirandamycin binding affinity to E. coli RNAp. The appropriate oligonucleotide primers
would be ordered for the amino acid substitutions described above. Site-directed mutagenesis
would be performed using standard procedures.78 To control for enzymatic function, each E.
coli mutant would be spread in 96-well plates on Nutrient agar and spotted with 100 μl serial
dilutions starting with a 200 μg/ml concentration of the tirandamycin-DMSO solution
described in aim 1. Furthermore, 100 μl of 20% DMSO by volume would also be spotted as a
control. Any E. coli mutants that cannot grow in the 20% DMSO solution would be assumed
to have a mutation that renders the enzyme inactive. The procedure explained in aim 2 would
be used to recrystallize each tirandamycin-RNAp complex for the E. coli mutants that become
tirandamycin-resistant to ensure allosteric changes in the enzyme are not the cause of any
change in the antibacterial activity of tirandamycin. By including these control experiments,
the mutations that cause tirandamycin resistance can be assumed to contribute to necessary
interactions for bacterial inhibition between the drug and RNAp amino acid residues.
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III. Significance
As an RNAp inhibitor, tirandamycin has an advantage over currently used antibacterials.
Rifamycin’s are currently the only class of RNAp inhibitors that have been approved for
clinical use.79 Rifamycin-resistant strains of S. aureus, S. pneumoniae, and E. coli have also
begun to evolve.80–84 This leaves relatively few competitors for antibacterials that act as RNAp
inhibitors. Additionally, because bacterial RNAp is an essential enzyme and highly conserved,
it is likely that antibacterial agents targeting this region would be potent against a wide variety
of bacteria.85 Bacterial RNAp are also vastly different from eukaryotic RNAp, so drugs that
target this enzyme have no effect on human RNAp, making this enzyme a key antibacterial
target.86 Tirandamycin also has shown little to no cell toxicity in human cells, making it a
promising option for further pharmaceutical research.5,11
Tirandamycin has a complex structure, like many natural other products, and many of its
derivatives have already been obtained by chemical synthesis.12–14 Comparatively, structurebased drug design commonly used in pharmaceutical research often lacks the ability to create
drugs that are as effective antibacterials as those produced through thousands of years of
evolution.87 It is therefore advantageous to utilize the naturally produced antibiotic
tirandamycin by uncovering its mode of action and making synthetic improvements upon the
compound to create the optimal molecule.
As bacteria continue to mutate and grow resistant to previously used antibacterial
compounds the need for a novel drug is always of great importance. Currently, the bacteria
vancomycin-resistant Enterococcus faecium, group A and B S. agalactiae, S. aureus, S.
pneumoniae and E. coli are all considered high-risk bacteria because they have continued to
evolve and become resistant to many of the commonly used antibacterials. While tirandamycin
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has shown antibacterial activity against all of these bacteria, many of its derivatives have not
yet been tested for antibacterial activity. This leaves a large gap in the knowledge of the impact
the natural product could have as a novel antibacterial drug. By exploring the varying
antibacterial activity of its derivatives against an array of high-risk bacteria, the full potential
of this promising antibacterial could be uncovered and lead to finding more potent naturally
occurring forms of the drug. The drug screening proposed in aim 1 would provide this
information.
Understanding the mechanism of action of tirandamycin would allow for the elucidation
of the structure-function relationship of tirandamycin and its many derivatives. Having this
information could lead to improving on the structure of tirandamycin to become a more potent
antibacterial. E. coli is a great target for this research as the need for a new, more potent
antibacterial against this bacterium is critical due to the sudden rise in multidrug resistant E.
coli. Aim 2 and 3 would allow for a deeper understanding of how tirandamycin and the other
related natural products in the tetramic acid family function. Assuming tirandamycin is an
allosteric inhibitor similar to streptolydigin, this could include increasing tirandamycins
binding affinity to the β and β' subunits of E. coli RNAp. Due to the increased risk associated
with E. coli, VRE, group A and B S. agalactiae, S. aureus, and S. pneumoniae and the high
potential of tirandamycin as a pharmaceutical drug, this research is a necessary next step for
antibacterial exploration.
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